Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jan 19;13(1):392.
doi: 10.1038/s41467-022-27960-2.

Immune-related adverse events and the balancing act of immunotherapy

Michael Conroy  1   2   3 , Jarushka Naidoo  4   5   6   7
Affiliations
Review

Immune-related adverse events and the balancing act of immunotherapy

Michael Conroy et al. Nat Commun. .

Abstract

The benefit from immune checkpoint inhibitors is tempered by immunologic toxicities, which involve diverse organs, have varying biology, onset time, and severity. Herein, we identify important areas of controversy and open research questions in the field of immune-related toxicity.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Innovation in immune-related adverse event research spans the preclinical setting (preclinical models exploring mechanisms and biomarkers), irAE prevention studies (based on genetic or microbial biomarkers and potential interventions), studies that focus on optimizing irAE diagnosis (based on biomarkers or imaging to improve diagnostic pathways), and lastly irAE treatment (prospective irAE trials to inform guidelines).
See this image and copyright information in PMC

References

    1. Hodi FS, et al. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. Lancet Oncol. 2018;19:1480–1492. doi: 10.1016/S1470-2045(18)30700-9. - DOI - PubMed
    1. Maher VE, et al. Analysis of the association between adverse events and outcome in patients receiving a programmed death protein 1 or programmed death ligand 1 antibody. J. Clin. Oncol. 2019;37:2730–2737. doi: 10.1200/JCO.19.00318. - DOI - PubMed
    1. Eggermont AMM, et al. Association between immune-related adverse events and recurrence-free survival among patients with stage III melanoma randomized to receive pembrolizumab or placebo: a secondary analysis of a randomized clinical trial. JAMA Oncol. 2020;6:519–527. doi: 10.1001/jamaoncol.2019.5570. - DOI - PMC - PubMed
    1. Shankar B, et al. Multisystem immune-related adverse events associated with immune checkpoint inhibitors for treatment of non-small cell lung cancer. JAMA Oncol. 2020;6:1952–1956. doi: 10.1001/jamaoncol.2020.5012. - DOI - PMC - PubMed
    1. Suresh K, Naidoo J. Lower survival in patients who develop pneumonitis following immunotherapy for lung cancer. Clin. Lung Cancer. 2020;21:e169–e170. doi: 10.1016/j.cllc.2019.10.009. - DOI - PubMed

Substances